Europe Diabetes Drugs Market - Size, Share & Trends Analysis

The Report Covers Europe Diabetes Drugs Companies and It is Segmented Into Drugs (insulin Drugs (basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, and Biosimilar Insulins), Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, Sglt-2 Inhibitors, Dpp-4 Inhibitors, Sulfonylureas, and Meglitinides), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists and Amylin Analogue), and Combination Drugs (insulin Combinations and Oral Combinations)) and Geography (United Kingdom, Germany, Italy, Spain, France, Russia, and the Rest of Europe). The Report Offers the Value (in USD) for the Above Segments.

本报告涵盖欧洲糖尿病药物市场，并根据药物类别（包括胰岛素药物（基础或长效胰岛素、短效胰岛素、传统人胰岛素和生物类似物胰岛素）、口服抗糖尿病药物（双胍类、α-葡萄糖苷酶抑制剂、多巴胺D2受体激动剂、SGLT-2抑制剂、DPP-4抑制剂、磺酰脲类和美格列奈类）、非胰岛素注射药物（GLP-1受体激动剂和氨基肽类似物）以及联合药物（胰岛素联合和口服联合））以及地理区域（英国、德国、意大利、西班牙、法国、俄罗斯和欧洲其他地区）进行细分。报告提供了上述各细分市场的价值（以美元计）。